Clinical trials: Liver Diseases, Alcoholic
NASH - Nonalcoholic Steatohepatitis, NAS
Hepatic Energy Fluxes in NASH and NAS Patients
Diseases along the nonalcoholic fatty liver disease spectrum, which are tightly coupled to the obesity epidemic, are soon to become the commonest indication for liver transplantation in the United States.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss
- Trial name
- NCT03997422
- Testing
- Vertical Sleeve Gastrectomy (VSG)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
Non-Alcoholic Fatty Liver Disease
Evaluation of Lipid Profile in Different Grades of Non-alcoholic Fatty Liver Disease Diagnosed by Ultrasound
Liver cells play a major role in the regulation of lipid metabolism. They are the principal location for lipoprotein and cholesterol synthesis.
- Trial name
- NCT05486429
- Testing
- Abdominal ultrasound and lipid profile
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Sohag University
Inpatient With End Stage Liver Disease
Is Access to Liver Transplantation Similar in Alcoholic or Not Patients?
The purpose of this study is to determine whether there are reasons other than medical reasons that could limit access to liver transplantation in alcoholic patients.
- Trial name
- TRANSALC (NCT01820819)
- Where
- France
- Volunteers
- 574 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
NAFLD
Fighting Fatty Liver in India
This study aims to build capacity in India by: 1. Developing tailored protocol methodologies for research including technical capability in imaging (MRI/S protocols \& customised software), dietary intervention delivery, dietary…
- Trial name
- FFL (NCT03844165)
- Testing
- Diet change (red rice), Yoga
- Where
- India
- Volunteers
- 84 people
- Sponsor
- University of Nottingham
Hepatitis, Alcoholic
Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis
ADDUP is an observational study of patients with alcoholic hepatitis. A structured interview is used to quantitatively estimate: 1. Alcohol use 2. Dietary intake 3.
- Trial name
- ADDUP (NCT02404636)
- Testing
- Interview
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University Hospital Birmingham
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Liver Fibrosis, Malnutrition
Nutritional Indices and Inflammatory Markers in MASLD
Metabolic Dysfunction-Associated steatotic Liver Diseases MASLD affects approximately 25 percent of population. Systemic inflammation plays role in MASLD progression.
- Conditions
- Liver Fibrosis, Malnutrition, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT07834905
- Volunteers
- 180 people
- Sponsor
- Assiut University
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD)
Tesamorelin Effects on Liver Fat and Histology in HIV
Liver disease is one of the leading co-morbidities of human immunodeficiency virus (HIV) infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30-40% of patients with HIV infection.
- Conditions
- Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT02196831
- Testing
- tesamorelin
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Massachusetts General Hospital
Non-Alcoholic Fatty Liver Disease, Central Obesity
12-Month Once-a-week HIIT Improves Body Adiposity and Liver Fat
Obesity and non-alcoholic fatty liver disease (NAFLD) are two related growing epidemics that are becoming pressing public health concerns.
- Trial name
- NCT03912272
- Testing
- High-intensity Interval Training, Usual Care Control
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- The University of Hong Kong
NAFLD
C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is characterized by an accumulation of fat in the liver, which is one of the most common forms of chronic liver disease in developed countries.
- Trial name
- NCT02083159
- Where
- South Korea
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Korea University
Nonalcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes (T2DM)
Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease
The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD).
- Trial name
- NCT03459079
- Testing
- Lanifibranor
- Where
- United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Florida
NAFLD, NASH
THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis)
The main objective of this cohort study is to determine genetic, clinical biologic and metabolic factors associated with patient heterogeneity in regards to severity of NAFLD at diagnosis as well as during the clinical course.
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis
- Trial name
- FRAMES (NCT04925362)
- Testing
- Biological specimens, Additional visit
- Volunteers
- 900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
PreDiabetes, NAFLD
Effects of Almonds in Glucose-intolerant Adults (AGAMEMNON)
Tree nuts - such as almonds - contribute to beneficial effects of the Mediterranean diet on risk for cardiovascular events, type 2 diabetes, dyslipidemia, hypertension, inflammation and non-alcoholic fatty liver disease.
- Trial name
- AGAMEMNON (NCT06413069)
- Testing
- Raw whole almonds
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Charite University, Berlin, Germany
Diabetes Mellitus, Type 2, Overweight and Obesity
Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study
Scientific evidence for the dietary treatment of type 2 diabetes (T2D) is insufficient, which is why the investigators aim to reform dietary recommendation to the overweight or obese patient with type 2 diabetes.
- Trial name
- CutDM-Hypo (NCT03814694)
- Testing
- CRHP Diet, CD Diet
- Where
- Denmark
- Volunteers
- 72 people
- Sponsor
- Bispebjerg Hospital
Fatty Liver, Fatty Liver, Nonalcoholic
Quantitative US for Evaluation of Hepatic Steatosis in NAFLD
The purpose of this study is to evaluate diagnostic performance of quantitative ultrasonographic parameters for the assessment of hepatic steatosis with find optimal cut-off values in patients with non-alcoholic fatty liver…
- Trial name
- NCT04462562
- Testing
- Quantitative US (Samsung Medison, RS85A)
- Where
- South Korea
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Non-Alcoholic Fatty Liver Disease
The Effect of Bariatric Surgery on Hepatic Metabolism in Non-Alcoholic Fatty Liver Disease
The purpose of this study is to investigate the mechanisms underlying bariatric surgery-induced resolution of non-alcoholic fatty liver disease.
- Trial name
- BASIC (NCT05551559)
- Testing
- bariatric surgery
- Where
- Finland
- Volunteers
- 180 people
- Sponsor
- Helsinki University Central Hospital
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Conditionally Increased Output (CIO) Enhanced Ultrasound System
This study aims to assess possible bioeffects that may be caused by the use of shear wave elastography (SWE) with conditionally increased acoustic output pressure (CIO).
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fatty Liver
- Trial name
- NCT05792423
- Testing
- GE ultrasound system with increased acoustic output settings
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Fatty Liver
The Effect of a Probiotic on Hepatic Steatosis
Non-alcoholic fatty liver disease (NAFLD) is an accumulation of fat and fibrous tissue in the liver. It is the most common cause of chronic liver disease in the United States.
- Trial name
- NCT00099723
- Testing
- VSL#3
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VSL Pharmaceuticals
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Efficacy and Safety of Guanabenz for Nonalcoholic Fatty Liver Disease
To investigate the efficacy and safety of 4 mg/day of WY-8678 (guanabenz acetate) and 8 mg/day of WY-8678 (guanabenz acetate) in patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH patients)…
- Trial name
- NCT05084404
- Testing
- Experimental: 4 mg/day of WY-8678 (guanabenz acetate), Experimental: 8 mg/day of WY-8678 (guanabenz acetate)
- Where
- Japan
- Volunteers
- 29 people
- Sponsor
- Yokohama City University
Non-Alcoholic Fatty Liver Disease, Gallstone Disease
Prevention of NAFLD and CVD Through Lifestyle Intervention
Prevention of non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) through lifestyle intervention (MAUCO+) is a clinical trial that aims to improve sarcopenia, aerobic capacity, body composition, and lipid…
- Trial name
- MAUCO+ (NCT05618626)
- Testing
- Physical exercise and dietary intervention for NAFLD
- Where
- Chile
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pontificia Universidad Catolica de Chile
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.